Gerwin Winter
About Gerwin Winter
Gerwin Winter is the Senior Vice President and Head of Europe at BeiGene, based in Basel, Switzerland, with extensive experience in the pharmaceutical industry.
Company
Currently, Gerwin Winter holds a pivotal role at BeiGene, serving as the Senior Vice President, Head of Europe. Based in Basel, Switzerland, he joined the company in March 2021. BeiGene is a global biotechnology company that specializes in developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer.
Title
Gerwin Winter is the Senior Vice President, Head of Europe at BeiGene. Additionally, he serves as the Chairman of SAIL in Bhutan, a non-profit healthcare organization he founded in 2018. His role at BeiGene involves overseeing the European operations and contributing to the company's mission of developing innovative cancer treatments.
Education and Expertise
Gerwin Winter has an extensive educational background. He earned his PharmD in pharmacy from Ludwig-Maximilians-Universität München. Furthermore, he holds a General Management MBA from CEDEP at INSEAD in Fontainebleau, France and attended the General Management Program at the University of Virginia Darden School of Business. His academic achievements have equipped him with substantial skills in general management and business development.
Background
Gerwin Winter has held numerous senior leadership roles in the pharmaceutical industry. His career spans roles such as General Manager at Bristol-Myers Squibb and Vice President, General Manager at Celgene. He played a crucial role in building European operations from scratch at Portola Pharmaceuticals and facilitated multiple drug launches during his tenure at these companies. He has worked in various international locations, showcasing his global professional experience.
Achievements
At BeiGene, Gerwin Winter leads the European operations, illuminating his capacity for high-level executive responsibilities. At Portola Pharmaceuticals, he was instrumental in building the company's European operations and facilitated its acquisition by Alexion. His tenure at Celgene saw the launch of multiple hematology drugs such as Revlimid®, Imnovid®, Vidaza®, Sprycel®, and Abraxane®. In 2018, he founded SAIL in Bhutan, focusing on preventing gastric cancer across the entire country, highlighting his dedication to healthcare advancements.